BLOOD CANCER UNITED INC: Form 990, tax year 2012

View the entire original 990 at ProPublica ↗

Organization
BLOOD CANCER UNITED INC (EIN 13-5644916)
Tax period
2012-07-01 to 2013-06-30
Filed
2014-02-12
IRS object ID
201430439349301123
Schema version
2012v2.3
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Timestamp2014-02-12T12:07:14-06:00Timestamp
Tax Period End Date2013-06-30TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

FieldValueIRS element (for citing)
Business Name Line1KPMG LLPBusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

FieldValueIRS element (for citing)
Address Line1345 PARK AVENUEAddressLine1
CityNEW YORKCity
StateNYState
ZIP Code101540102ZIPCode
FieldValueIRS element (for citing)
Return Type990ReturnType
Tax Period Begin Date2012-07-01TaxPeriodBeginDate

Filer Filer

FieldValueIRS element (for citing)
EIN135644916EIN

Name Name

FieldValueIRS element (for citing)
Business Name Line1THE LEUKEMIA & LYMPHOMA SOCIETYINCBusinessNameLine1
FieldValueIRS element (for citing)
Name ControlLEUKNameControl
Phone9149495213Phone

US Address USAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1
Address Line2ROOM/SUITE 310AddressLine2
CityWHITE PLAINSCity
StateNYState
ZIP Code10605ZIPCode

Officer Officer

FieldValueIRS element (for citing)
NameROSEMARIE LOFFREDOName
TitleCAO & CFOTitle
Phone9149495213Phone
Date Signed2014-02-12DateSigned
Authorize Third PartytrueAuthorizeThirdParty

Preparer Preparer

FieldValueIRS element (for citing)
NameKPMG LLPName
Phone2127589700Phone
Date Prepared2014-02-12DatePrepared
FieldValueIRS element (for citing)
Tax Year2012TaxYear
Build TS2015-11-30 17:44:51ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Name Of Principal Officer PersonLOUIS J DEGENNAROINTERIM PRESCEONameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1
CityWHITE PLAINSCity
StateNYState
ZIP Code10605ZIPCode
FieldValueIRS element (for citing)
Gross Receipts376034972GrossReceipts
Group Return For AffiliatesfalseGroupReturnForAffiliates
Organization501c3XOrganization501c3
Web SiteWWW.LLS.ORGWebSite
Type Of Organization CorporationXTypeOfOrganizationCorporation
Year Formation1949YearFormation
State Legal DomicileNYStateLegalDomicile
Activity Or Mission DescriptionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.ActivityOrMissionDescription
Nbr Voting Members Governing Body22NbrVotingMembersGoverningBody
Nbr Independent Voting Members22NbrIndependentVotingMembers
Total Nbr Employees1580TotalNbrEmployees
Total Nbr Volunteers3000000TotalNbrVolunteers
Total Gross UBI0TotalGrossUBI
Contributions Grants Prior Year282672073ContributionsGrantsPriorYear
Contributions Grants Current Year279789665ContributionsGrantsCurrentYear
Program Service Revenue CY0ProgramServiceRevenueCY
Investment Income Prior Year8039879InvestmentIncomePriorYear
Investment Income Current Year8133222InvestmentIncomeCurrentYear
Other Revenue Prior Year2111041OtherRevenuePriorYear
Other Revenue Current Year2435580OtherRevenueCurrentYear
Total Revenue Prior Year292822993TotalRevenuePriorYear
Total Revenue Current Year290358467TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year115731627GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY117726007GrantsAndSimilarAmntsCY
Benefits Paid To Members CY0BenefitsPaidToMembersCY
Salaries Etc Prior Year86776477SalariesEtcPriorYear
Salaries Etc Current Year90034581SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year10175403TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY10134488TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year48057833TotalFundrsngExpCurrentYear
Other Expense Prior Year79711007OtherExpensePriorYear
Other Expenses Current Year89083589OtherExpensesCurrentYear
Total Expenses Prior Year292394514TotalExpensesPriorYear
Total Expenses Current Year306978665TotalExpensesCurrentYear
Revenues Less Expenses Prior Year428479RevenuesLessExpensesPriorYear
Revenues Less Expenses CY-16620198RevenuesLessExpensesCY
Total Assets BOY223445924TotalAssetsBOY
Total Assets EOY236325556TotalAssetsEOY
Total Liabilities BOY109397145TotalLiabilitiesBOY
Total Liabilities EOY135316123TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY114048779NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY101009433NetAssetsOrFundBalancesEOY
Info In Schedule O Part IIIXInfoInScheduleOPartIII
Mission DescriptionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.MissionDescription
Significant New Program ServicesfalseSignificantNewProgramServices
Significant ChangefalseSignificantChange
Expense76025725Expense
Grants72086215Grants
DescriptionA) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. (CONTINUED ON SCHEDULE O) TO DATE, LLS HAS INVESTED ALMOST 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2013, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 72 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2013, FOR THE SECOND YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN THREE OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - THE MALIGNANT STEM CELL IN AML AND MDS - NON-CUTANEOUS T-CELL LEUKEMIAS AND LYMPHOMAS - HIGH RISK MYELOMA CASES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON AS POSSIBLE. THE PROGRAM INCLUDES: - THE ACADEMIC CONCIERGE DIVISION IDENTIFIES ESPECIALLY PROMISING LLS-FUNDED GRANT PROJECTS AND PROVIDES ADDITIONAL SUPPORT TO ADVANCE SELECTED PROJECTS TO THE PRODUCT STAGE. - THE BIOTECHNOLOGY ACCELERATOR DIVISION PARTNERS LLS WITH COMPANIES TO COMBINE SCIENTIFIC AND FINANCIAL RESOURCES AND ACCELERATE THE DEVELOPMENT OF POTENTIAL BLOOD CANCER THERAPIES THAT OTHERWISE MIGHT NOT BE PRIORITIZED BY THE COMPANY. - THE CLINICAL TRIALS DIVISION BRINGS CLINICAL TRIALS TO BLOOD CANCER PATIENTS IN THEIR COMMUNITIES, INCLUDING UNDER-REPRESENTED POPULATIONS, AND WITH THE ULTIMATE GOAL OF INCREASING PATIENT ENROLLMENT IN BLOOD CANCER TRIALS.Description

Activity2 Activity2

FieldValueIRS element (for citing)
Expense107397528Expense
Grants45639792Grants
DescriptionB) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1,129,813 PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS A FREE, COMPREHENSIVE ARRAY OF SERVICES TO BLOOD CANCER PATIENTS AND THEIR FAMILIES, VOLUNTEER CAREGIVERS AND ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. (CONTINUED ON SCHEDULE O) LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH AND SPANISH. - 920,398 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2013 FINANCIAL ASSISTANCE IN 2013, A COMBINED 45,639,792 DOLLARS WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,989,442) AND CO-PAY ASSISTANCE PROGRAMS (42,650,350). PATIENT FINANCIAL AID PROGRAM FOR MORE THAN 46 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL AID PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL AID FUNDS ARE SUBJECT TO AVAILABILITY. - 29,894 PATIENTS RECEIVED FINANCIAL AID IN 2013 CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,259 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2013 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 34,809 PATIENT AND CAREGIVER PARTICIPANTS IN 2013 - 13,182 HEALTHCARE PROFESSIONAL PARTICIPANTS IN 2013 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 2,412 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 54 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2013. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 415 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 843 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 9,452 PARTICIPANTS IN FAMILY SUPPORT GROUPS IN 2013 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 6,322 FIRST CONNECTIONS IN 2013Description

Activity3 Activity3

FieldValueIRS element (for citing)
Expense41981280Expense
DescriptionC) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION INFORMATION RESOURCE CENTER PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. (CONTINUED ON SCHEDULE O) LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 6 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 54,682 INQUIRIES IN 2013 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, PATIENT FINANCIAL AID, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL-TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2013, 14 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.Description

Activity Other ActivityOther

FieldValueIRS element (for citing)
Expense9062232Expense
DescriptionD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.Description
FieldValueIRS element (for citing)
Total Of Other Program Service Exp9062232TotalOfOtherProgramServiceExp
Total Program Service Expense234466765TotalProgramServiceExpense
Described In501 C3trueDescribedIn501C3
Schedule B RequiredtrueScheduleBRequired
Political ActivitiesfalsePoliticalActivities
Lobbying ActivitiestrueLobbyingActivities
Subject To Proxy TaxfalseSubjectToProxyTax
Donor Advised FundsfalseDonorAdvisedFunds
Conservation EasementsfalseConservationEasements
Collections Of ArttrueCollectionsOfArt
Credit CounselingfalseCreditCounseling
Term Or Permanent EndowmentstrueTermOrPermanentEndowments
Report Land Bldg EquiptrueReportLandBldgEquip
Report Invest Oth SecuritiestrueReportInvestOthSecurities
Report Prog Rel InvestfalseReportProgRelInvest
Report Other AssetsfalseReportOtherAssets
Report Other LiabilitiesfalseReportOtherLiabilities
Report Fin48 FootnotetrueReportFin48Footnote
Independent Audit Financial StmtfalseIndependentAuditFinancialStmt
Consolidated Audit Financial StmttrueConsolidatedAuditFinancialStmt
SchoolfalseSchool
Foreign OfficetrueForeignOffice
Foreign ActivitiestrueForeignActivities
More Than5000 K To OrganizationstrueMoreThan5000KToOrganizations
More Than5000 K To IndividualsfalseMoreThan5000KToIndividuals
Professional FundraisingtrueProfessionalFundraising
Fundraising ActivitiestrueFundraisingActivities
GamingtrueGaming
HospitalfalseHospital
Grants To OrganizationstrueGrantsToOrganizations
Grants To IndividualstrueGrantsToIndividuals
Schedule J RequiredtrueScheduleJRequired
Tax Exempt BondsfalseTaxExemptBonds
Excess Benefit TransactionfalseExcessBenefitTransaction
Prior Excess Benefit TransactionfalsePriorExcessBenefitTransaction
Loan To Officer Or DQPfalseLoanToOfficerOrDQP
Grant To Related PersonfalseGrantToRelatedPerson
Bsnss Rltnshp With OrganizationfalseBsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family MemberfalseBsnssRltnshpThruFamilyMember
Officer Entity With Bsnss RltnshpfalseOfficerEntityWithBsnssRltnshp
Deductible Non Cash ContributionstrueDeductibleNonCashContributions
Deductible Contributions Of ArtfalseDeductibleContributionsOfArt
TerminatedfalseTerminated
Partial LiquidationfalsePartialLiquidation
Disregarded EntityfalseDisregardedEntity
Related EntitytrueRelatedEntity
Related Org Controlled EntitytrueRelatedOrgControlledEntity
Transaction Related EntitytrueTransactionRelatedEntity
Transfers To Exempt Non Chrtbl OrgfalseTransfersToExemptNonChrtblOrg
Activities Conducted PartnershipfalseActivitiesConductedPartnership
Schedule O RequiredtrueScheduleORequired
Number Forms Transmitted With10961222NumberFormsTransmittedWith1096
Number W2 G Included26NumberW2GIncluded
Compliance With Backup WitholdingtrueComplianceWithBackupWitholding
Number Of Employees1580NumberOfEmployees
Employment Tax Returns FiledtrueEmploymentTaxReturnsFiled
Unrelated Business IncomefalseUnrelatedBusinessIncome
Foreign Financial AccounttrueForeignFinancialAccount
Name Of Foreign CountryCANameOfForeignCountry
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTrans
Taxable Party NotificationfalseTaxablePartyNotification
Non Deductible ContributionstrueNonDeductibleContributions
Non Deductible DisclosuretrueNonDeductibleDisclosure
Quid Pro Quo ContributionstrueQuidProQuoContributions
Quid Pro Quo DisclosuretrueQuidProQuoDisclosure
Form8282 Property Disposed OffalseForm8282PropertyDisposedOf
Funds To Pay PremiumsfalseFundsToPayPremiums
Premiums PaidfalsePremiumsPaid
Indoor Tanning ServicesfalseIndoorTanningServices
Info In Schedule O Part VIXInfoInScheduleOPartVI
Nbr Voting Governing Body Members22NbrVotingGoverningBodyMembers
Number Independent Voting Members22NumberIndependentVotingMembers
Family Or Business RelationshipfalseFamilyOrBusinessRelationship
Delegation Of Management DutiesfalseDelegationOfManagementDuties
Changes To Organizing DocsfalseChangesToOrganizingDocs
Material Diversion Or MisusefalseMaterialDiversionOrMisuse
Members Or StockholderstrueMembersOrStockholders
Election Of Board MemberstrueElectionOfBoardMembers
Decisions Subject To ApprovaltrueDecisionsSubjectToApproval
Minutes Of Governing BodytrueMinutesOfGoverningBody
Minutes Of CommitteestrueMinutesOfCommittees
Officer Mailing AddressfalseOfficerMailingAddress
Local ChapterstrueLocalChapters
Policies Reference ChapterstruePoliciesReferenceChapters
Form990 Provided To Governing BodytrueForm990ProvidedToGoverningBody
Conflict Of Interest PolicytrueConflictOfInterestPolicy
Annual Disclosure Covered PersonstrueAnnualDisclosureCoveredPersons
Regular Monitoring EnforcementtrueRegularMonitoringEnforcement
Whistleblower PolicytrueWhistleblowerPolicy
Document Retention PolicytrueDocumentRetentionPolicy
Compensation Process CEOtrueCompensationProcessCEO
Compensation Process OthertrueCompensationProcessOther
Investment In Joint VenturefalseInvestmentInJointVenture
States Where Copy Of Return Is FiledAKStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledALStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledARStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledAZStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledCAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledCOStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledCTStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledDEStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledDCStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledFLStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledGAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledHIStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledIDStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledILStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledINStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledKSStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledKYStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledLAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMDStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMEStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMIStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMNStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMOStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMSStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNHStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNJStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNMStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNEStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNYStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledOHStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledOKStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledORStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledPAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledPRStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledRIStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledSCStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledTNStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledUTStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledVAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledWAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledWIStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledWVStatesWhereCopyOfReturnIsFiled
Own WebsiteXOwnWebsite
Upon RequestXUponRequest

The Books Are In Care Of TheBooksAreInCareOf

FieldValueIRS element (for citing)
Name PersonROSEMARIE LOFFREDONamePerson
Telephone Number9149495213TelephoneNumber

Address US AddressUS

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1
CityWHITE PLAINSCity
StateNYState
ZIP Code10605ZIPCode
FieldValueIRS element (for citing)
Info In Schedule O Part VIIXInfoInScheduleOPartVII

Form990 Part VII Section A Form990PartVIISectionA (30 entries)

TitleTitleAverage Hours Per WeekAverageHoursPerWeekIndividual Trustee Or DirectorIndividualTrusteeOrDirectorReportable Comp From OrganizationReportableCompFromOrganizationReportable Comp From Related OrgsReportableCompFromRelatedOrgsOther CompensationOtherCompensationOfficerOfficerHighest Compensated EmployeeHighestCompensatedEmployeeFormerFormer
JAMES A BECK
BOD MEMBER2.00X000
WILLIAM G BEHNKE
BOD MEMBER2.00X000
JORGE L BENITEZ
BOD MEMBER2.00X000
PETER B BROCK
BOD MEMBER2.00X000
A DANA CALLOW JR
BOD MEMBER2.00X000
SCOTT A CARROLL
BOD MEMBER2.00X000
ELIZABETH J CLARK
BOD MEMBER2.00X000
RODMAN N MYERS
LIFE MEMBER2.00X000
JAMES H DAVIS PHD
VICE CHAIR2.00X000X
TIMOTHY DURST
CHAIR2.00X000X
BERNARD H GARIL
BOD MEMBER2.00X000
PAMELA JO HAYLOCK
BOD MEMBER2.00X000
RAANAN HOROWITZ
BOD MEMBER2.00X000
RICHARD M JEANNERET
BOD MEMBER2.00X000
JORGE CORTES
BOD MEMBER2.00X000
JOSEPH B KELLEY
BOD MEMBER2.00X000
MARIE V MCDEMMOND
BOD MEMBER2.00X000
MATTHEW WINTER
BOD MEMBER2.00X000
STEVEN T ROSENMDFACP
BOD MEMBER2.00X000
KENNETH M SCHWARTZ
SECRETARY/TR2.00X000X
KATHRYN C VECELLIO
BOD MEMBER2.00X000
LOUISE E WARNER
BOD MEMBER2.00X000
JOHN WALTER
PRESIDENT &45.00573622054985X
JAMES T NANGLE
SVP & CFO45.00236728046062X
LOUIS DEGENNARO
CHIEF MISSIO45.00382058041269X
RICHARD WINNEKER
SVP RESEARCH45.00296242018732X
GEORGE OMIROS
CHIEF CAMPAI45.00279616041135X
KETING CHU
VP RES THERA45.00273019017758X
DAVID TIMKO
SVP VOLUNTEE45.00252850040191X
NANCY KLEIN
CHIEF MKTG &0.00451541022711X
FieldValueIRS element (for citing)
Total Reportable Comp From Org2745676TotalReportableCompFromOrg
Total Other Compensation282843TotalOtherCompensation
Number Individuals GT100 K108NumberIndividualsGT100K
Formers ListedtrueFormersListed
Total Comp GT150 KtrueTotalCompGT150K
Compensation From Other SourcesfalseCompensationFromOtherSources

Contractor Compensation ContractorCompensation (5 entries)

Address Line1AddressOfContractor/AddressUS/AddressLine1CityAddressOfContractor/AddressUS/CityStateAddressOfContractor/AddressUS/StateZIP CodeAddressOfContractor/AddressUS/ZIPCodeDescription Of ServicesDescriptionOfServicesCompensationCompensation
MAIL AMERICA
174 ELKTON FARM RDFORESTVA24551FUNDRAISING SER4010903
INFOCISION
325 SPRINGSIDE DRIVEAKRONOH44333FUNDRASING SERV1791410
PARADYZ MATERA
5 HANOVER SQUARENEW YORKNY10004FUNDRAISING SER1766306
ROBERT MICHAEL EDUCATIONAL INSTITUT
101 LAUREL ROADVORHEESNJ08043EDUCATIONAL SER1671489
DIRECT PRINT COMMUNICATIONS
201 EAST SANDPOINTESANTA ANACA92707FUNDRAISING1382841
FieldValueIRS element (for citing)
Number Of Contractors GT100 K47NumberOfContractorsGT100K
Federated Campaigns2264122FederatedCampaigns
Fundraising Events161261897FundraisingEvents
Related Organizations681316RelatedOrganizations
All Other Contributions115582330AllOtherContributions
Noncash Contributions1094571NoncashContributions
Total Contributions279789665TotalContributions

Investment Income InvestmentIncome

FieldValueIRS element (for citing)
Total Revenue Column2256195TotalRevenueColumn
Exclusion$2,256,195ExclusionAmount

Royalties Revenue RoyaltiesRevenue

FieldValueIRS element (for citing)
Total Revenue Column4441TotalRevenueColumn
Exclusion$4,441ExclusionAmount

Gross Amount Sales Assets GrossAmountSalesAssets

FieldValueIRS element (for citing)
Securities57803147Securities

Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses

FieldValueIRS element (for citing)
Securities51926120Securities

Gain Or Loss GainOrLoss

FieldValueIRS element (for citing)
Securities5877027Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

FieldValueIRS element (for citing)
Total Revenue Column5877027TotalRevenueColumn
Exclusion$5,877,027ExclusionAmount
FieldValueIRS element (for citing)
Gross Income Fundraising Events33429268GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events161261897CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses33429268FundraisingDirectExpenses
Gross Income Gaming778030GrossIncomeGaming
Gaming Direct Expenses321117GamingDirectExpenses

Net Income From Gaming NetIncomeFromGaming

FieldValueIRS element (for citing)
Total Revenue Column456913TotalRevenueColumn
Related Or Exempt Function Income456913RelatedOrExemptFunctionIncome

Other Revenue Misc OtherRevenueMisc (2 entries)

DescriptionDescriptionBusiness CodeBusinessCodeTotal Revenue ColumnTotalRevenueColumnExclusionExclusionAmount
GRANT TERMINATION5419001844147$1,844,147
OTHER MISCELLANEOUS900099130079$130,079
FieldValueIRS element (for citing)
Total Other Revenue1974226TotalOtherRevenue

Total Revenue TotalRevenue

FieldValueIRS element (for citing)
Total Revenue Column290358467TotalRevenueColumn
Related Or Exempt Function Income456913RelatedOrExemptFunctionIncome
Exclusion$10,111,889ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

FieldValueIRS element (for citing)
Total69323914Total
Program Services69323914ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

FieldValueIRS element (for citing)
Total45639792Total
Program Services45639792ProgramServices

Foreign Grants ForeignGrants

FieldValueIRS element (for citing)
Total2762301Total
Program Services2762301ProgramServices

Comp Current Officers Directors CompCurrentOfficersDirectors

FieldValueIRS element (for citing)
Total917839Total
Program Services678319ProgramServices
Management And General110907ManagementAndGeneral
Fundraising128613Fundraising

Other Salaries And Wages OtherSalariesAndWages

FieldValueIRS element (for citing)
Total68352738Total
Program Services50515387ProgramServices
Management And General8259440ManagementAndGeneral
Fundraising9577911Fundraising

Pension Plan Contributions PensionPlanContributions

FieldValueIRS element (for citing)
Total4238353Total
Program Services2959935ProgramServices
Management And General531305ManagementAndGeneral
Fundraising747113Fundraising

Other Employee Benefits OtherEmployeeBenefits

FieldValueIRS element (for citing)
Total11672840Total
Program Services8151949ProgramServices
Management And General1463265ManagementAndGeneral
Fundraising2057626Fundraising

Payroll Taxes PayrollTaxes

FieldValueIRS element (for citing)
Total4852811Total
Program Services3389053ProgramServices
Management And General608331ManagementAndGeneral
Fundraising855427Fundraising

Fees For Services Legal FeesForServicesLegal

FieldValueIRS element (for citing)
Total659004Total
Program Services373369ProgramServices
Management And General111307ManagementAndGeneral
Fundraising174328Fundraising

Fees For Services Accounting FeesForServicesAccounting

FieldValueIRS element (for citing)
Total215134Total
Program Services121887ProgramServices
Management And General36336ManagementAndGeneral
Fundraising56911Fundraising

Fees For Services Lobbying FeesForServicesLobbying

FieldValueIRS element (for citing)
Total637152Total
Program Services360986ProgramServices
Management And General107617ManagementAndGeneral
Fundraising168549Fundraising

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total10134488Total
Fundraising10134488Fundraising

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

FieldValueIRS element (for citing)
Total223721Total
Program Services126754ProgramServices
Management And General37787ManagementAndGeneral
Fundraising59180Fundraising

Fees For Services Other FeesForServicesOther

FieldValueIRS element (for citing)
Total18094016Total
Program Services10251427ProgramServices
Management And General3056114ManagementAndGeneral
Fundraising4786475Fundraising

Advertising Advertising

FieldValueIRS element (for citing)
Total13394628Total
Program Services6552320ProgramServices
Management And General2306078ManagementAndGeneral
Fundraising4536230Fundraising

Office Expenses OfficeExpenses

FieldValueIRS element (for citing)
Total27205388Total
Program Services13221915ProgramServices
Management And General4238769ManagementAndGeneral
Fundraising9744704Fundraising

Information Technology InformationTechnology

FieldValueIRS element (for citing)
Total4892378Total
Program Services2771847ProgramServices
Management And General826331ManagementAndGeneral
Fundraising1294200Fundraising

Occupancy Occupancy

FieldValueIRS element (for citing)
Total8610084Total
Program Services6187615ProgramServices
Management And General1059436ManagementAndGeneral
Fundraising1363033Fundraising

Travel Travel

FieldValueIRS element (for citing)
Total4263241Total
Program Services3034995ProgramServices
Management And General551923ManagementAndGeneral
Fundraising676323Fundraising

Conferences Meetings ConferencesMeetings

FieldValueIRS element (for citing)
Total4313049Total
Program Services3605205ProgramServices
Management And General314856ManagementAndGeneral
Fundraising392988Fundraising

Depreciation Depletion DepreciationDepletion

FieldValueIRS element (for citing)
Total2987271Total
Program Services1921375ProgramServices
Management And General392513ManagementAndGeneral
Fundraising673383Fundraising

Insurance Insurance

FieldValueIRS element (for citing)
Total598330Total
Program Services403614ProgramServices
Management And General70768ManagementAndGeneral
Fundraising123948Fundraising

Other Expenses OtherExpenses (2 entries)

DescriptionDescriptionTotalTotalProgram ServicesProgramServicesManagement And GeneralManagementAndGeneralFundraisingFundraising
MISCELLANEOUS26540511948374313112392565
DUES & SUBSCRIPTIONS33614216443257872113838

Total Functional Expenses TotalFunctionalExpenses

FieldValueIRS element (for citing)
Total306978665Total
Program Services234466765ProgramServices
Management And General24454067ManagementAndGeneral
Fundraising48057833Fundraising
FieldValueIRS element (for citing)
Joint CostsXJointCosts

Total Joint Costs TotalJointCosts

FieldValueIRS element (for citing)
Total16986590Total
Program Services9382892ProgramServices
Fundraising7603698Fundraising

Cash Non Interest Bearing CashNonInterestBearing

FieldValueIRS element (for citing)
BOY6532613BOY
EOY5620937EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

FieldValueIRS element (for citing)
BOY17034917BOY
EOY19656020EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

FieldValueIRS element (for citing)
BOY5178782BOY
EOY7252079EOY

Accounts Receivable AccountsReceivable

FieldValueIRS element (for citing)
BOY264507BOY
EOY81719EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

FieldValueIRS element (for citing)
BOY5875009BOY
EOY4851345EOY
FieldValueIRS element (for citing)
Land Buildings Equipment Basis21600484LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec11006325LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

FieldValueIRS element (for citing)
BOY6641060BOY
EOY10594159EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

FieldValueIRS element (for citing)
BOY138026930BOY
EOY112406398EOY

Investments Other Securities InvestmentsOtherSecurities

FieldValueIRS element (for citing)
BOY43892106BOY
EOY75862899EOY

Total Assets TotalAssets

FieldValueIRS element (for citing)
BOY223445924BOY
EOY236325556EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

FieldValueIRS element (for citing)
BOY19660610BOY
EOY20652928EOY

Grants Payable GrantsPayable

FieldValueIRS element (for citing)
BOY72815341BOY
EOY80460957EOY

Deferred Revenue DeferredRevenue

FieldValueIRS element (for citing)
BOY16921194BOY
EOY34202238EOY

Total Liabilities TotalLiabilities

FieldValueIRS element (for citing)
BOY109397145BOY
EOY135316123EOY
FieldValueIRS element (for citing)
Follow SFAS117XFollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

FieldValueIRS element (for citing)
BOY100978174BOY
EOY90324737EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

FieldValueIRS element (for citing)
BOY10221074BOY
EOY7775266EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

FieldValueIRS element (for citing)
BOY2849531BOY
EOY2909430EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY114048779BOY
EOY101009433EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY223445924BOY
EOY236325556EOY
FieldValueIRS element (for citing)
Info In Schedule O Part XIXInfoInScheduleOPartXI
Reconcilation Revenue Expenses-16620198ReconcilationRevenueExpenses
Reconciliation Unrealized Invest3666259ReconciliationUnrealizedInvest
Reconcilation Other Changes-85407ReconcilationOtherChanges
Info In Schedule O Part XIIXInfoInScheduleOPartXII
Method Of Accounting AccrualXMethodOfAccountingAccrual
Accountant Compile Or ReviewtrueAccountantCompileOrReview
FS AuditedtrueFSAudited

FS Audited Basis FSAuditedBasis

FieldValueIRS element (for citing)
Financial Statement ConsolidatedXFinancialStatementConsolidated
FieldValueIRS element (for citing)
Audit CommitteetrueAuditCommittee
Federal Grant Audit RequiredfalseFederalGrantAuditRequired

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Publicly Supported Org170b1 AviXPubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years269156149CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years238668944CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years270731343CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year283279625CurrentTaxYearMinus1Year
Current Tax Year280246578CurrentTaxYear
Total1342082639Total

Total170 Total170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years269156149CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years238668944CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years270731343CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year283279625CurrentTaxYearMinus1Year
Current Tax Year280246578CurrentTaxYear
Total1342082639Total
FieldValueIRS element (for citing)
Amounts Subst Contributors Total141092274AmountsSubstContributorsTotal
Public Support Total1701200990365PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years6950554CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years4962639CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years3145637CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year2705046CurrentTaxYearMinus1Year
Current Tax Year2260636CurrentTaxYear
Total20024512Total

Other Income170 OtherIncome170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years2816918CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years1925834CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years1779485CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year1502044CurrentTaxYearMinus1Year
Current Tax Year1974227CurrentTaxYear
Total9998508Total
FieldValueIRS element (for citing)
Total Support1372105659TotalSupport
Gross Receipts From Admissions Etc179352415GrossReceiptsFromAdmissionsEtc
Public Support Pertcentage1700.87530PublicSupportPertcentage170
Public Support Pertcent Prior Year0.91310PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170XThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

FieldValueIRS element (for citing)
Contributor NumberRESTRICTEDContributorNumber

Contributor Name Business ContributorNameBusiness

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor Address US ContributorAddressUS

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Aggregate ContributionsRESTRICTEDAggregateContributions

Schedule C IRS990ScheduleC

FieldValueIRS element (for citing)
VolunteerstrueVolunteers
Paid Staff Or ManagementtruePaidStaffOrManagement
Media AdvertisementsfalseMediaAdvertisements
Mailings MembersfalseMailingsMembers
Publications Or BroadcasttruePublicationsOrBroadcast
Publications Or Broadcast$114,447PublicationsOrBroadcastAmount
Grants Other OrganizationsfalseGrantsOtherOrganizations
Direct Contact LegislatorstrueDirectContactLegislators
Direct Contact Legislators$538,408DirectContactLegislatorsAmount
Rallies DemonstrationstrueRalliesDemonstrations
Rallies Demonstrations$132,952RalliesDemonstrationsAmount
Other ActivitiestrueOtherActivities
Other Activities$637,152OtherActivitiesAmount
Total Lobbying Expenditures IIB1422959TotalLobbyingExpendituresIIB
Not Described In501c3falseNotDescribedIn501c3

Form990 Schedule C Part IV Form990ScheduleCPartIV

FieldValueIRS element (for citing)
Return ReferenceSCHEDULE C, PART II-B, LINE 1ReturnReference
ExplanationLLS IS A MEMBER OF A NUMBER OF COALITIONS INCLUDING NATIONAL COALITION FOR CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, FRIENDS OF CANCER RESEARCH, CANCER LEADERSHIP COUNCIL, PATIENT ADVOCATE FOUNDATION, AMERICA ASSOCIATION FOR CANCER RESEARCH, CHILDREN'S CAUSE FOR CANCER ADVOCACY AND THE ANTICANCER AGENT DEVELOPMENT AND VALIDATION WORKSHOP. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.Explanation

Schedule D IRS990ScheduleD

FieldValueIRS element (for citing)
Collect Used For Public ExhibitionXCollectUsedForPublicExhibition
Solicited Assets For SalefalseSolicitedAssetsForSale

Current Year CurrentYear

FieldValueIRS element (for citing)
Beginning Of Year Balance6000186BeginningOfYearBalance
Investment Earnings Or Losses482520InvestmentEarningsOrLosses
Grants Or Scholarships-450000GrantsOrScholarships
Administrative Expenses-5049AdministrativeExpenses
End Of Year Balance6027657EndOfYearBalance

Current Year Minus1 Year CurrentYearMinus1Year

FieldValueIRS element (for citing)
Beginning Of Year Balance6059994BeginningOfYearBalance
Investment Earnings Or Losses48916InvestmentEarningsOrLosses
Administrative Expenses-9992AdministrativeExpenses
End Of Year Balance6000186EndOfYearBalance

Current Year Minus2 Years CurrentYearMinus2Years

FieldValueIRS element (for citing)
Beginning Of Year Balance5023902BeginningOfYearBalance
Contributions111064Contributions
Investment Earnings Or Losses938068InvestmentEarningsOrLosses
Administrative Expenses-13040AdministrativeExpenses
End Of Year Balance6059994EndOfYearBalance

Current Year Minus3 Years CurrentYearMinus3Years

FieldValueIRS element (for citing)
Beginning Of Year Balance4481610BeginningOfYearBalance
Investment Earnings Or Losses563236InvestmentEarningsOrLosses
Administrative Expenses-20944AdministrativeExpenses
End Of Year Balance5023902EndOfYearBalance

Current Year Minus4 Years CurrentYearMinus4Years

FieldValueIRS element (for citing)
Beginning Of Year Balance5228375BeginningOfYearBalance
Investment Earnings Or Losses730333InvestmentEarningsOrLosses
Administrative Expenses-16432AdministrativeExpenses
End Of Year Balance4481610EndOfYearBalance
FieldValueIRS element (for citing)
Permanent Endowment EOY Balance0.48000PermanentEndowmentEOYBalance
Term Endowment EOY Balance0.52000TermEndowmentEOYBalance
Endowments Held By Unrelated OrgsfalseEndowmentsHeldByUnrelatedOrgs
Endowments Held By Related OrgsfalseEndowmentsHeldByRelatedOrgs

Leasehold Improvements LeaseholdImprovements

FieldValueIRS element (for citing)
Other Cost Or Other Basis859421OtherCostOrOtherBasis
Depreciation380255Depreciation
Book Value479166BookValue

Equipment Equipment

FieldValueIRS element (for citing)
Other Cost Or Other Basis18564912OtherCostOrOtherBasis
Depreciation8800199Depreciation
Book Value9764713BookValue

Other Land Buildings OtherLandBuildings

FieldValueIRS element (for citing)
Other Cost Or Other Basis2176151OtherCostOrOtherBasis
Depreciation1825871Depreciation
Book Value350280BookValue
FieldValueIRS element (for citing)
Total Of Book Value Land Buildings10594159TotalOfBookValueLandBuildings

Other Securities OtherSecurities (5 entries)

DescriptionDescriptionBook ValueBookValueMethod Of ValuationMethodOfValuation
FUND OF HEDGE FUNDS- OPERATING69452037F
LIMITED PARTNERSHIP EQUITIES-OPERATI2492002F
FUND OF HEDGE FUNDS-ENDOWMENT2317410F
457B PLAN1357371F
LIMITED PARTNERSHIP EQUITIES-ENDOWME244079F
FieldValueIRS element (for citing)
Total Of Book Value Securities75862899TotalOfBookValueSecurities
Footnote In Part XIIIXFootnoteInPartXIII
Tot Revenue Etc Audited Fincl Stmt314316096TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments3666259NetUnrealizedGainsInvestments
Donated Srvc And Use Of Facilities7750188DonatedSrvcAndUseOfFacilities
Other Revenues13446219OtherRevenues
Revenue Not Rptd F99024862666RevenueNotRptdF990
Revenue Subtotal289453430RevenueSubtotal
Investment Expenses Not Included223721InvestmentExpensesNotIncluded
Other Revenues Not Included681316OtherRevenuesNotIncluded
Revenue Not Rptd On Fin Stmt905037RevenueNotRptdOnFinStmt
Total Revenue Per Form990290358467TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt327691856TotExpensesEtcAuditedFinclStmt
Donated Services Use Of Facilities7750188DonatedServicesUseOfFacilities
Other Expenses Included13186724OtherExpensesIncluded
Expenses Not Rptd F99020936912ExpensesNotRptdF990
Expenses Subtotal306754944ExpensesSubtotal
Investment Expenses Not Included2223721InvestmentExpensesNotIncluded2
Expenses Not Rptd On Fin Stmt223721ExpensesNotRptdOnFinStmt
Total Expenses Per Form990306978665TotalExpensesPerForm990

Form990 Schedule D Part XIII Form990ScheduleDPartXIII (7 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
COLLECTIONS AND RELATION TO EXEMPT PURPOSESCHEDULE D, PAGE 2, PART III, LINE 4THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
INTENDED USES FOR ENDOWMENT FUNDSSCHEDULE D, PAGE 2, PART V, LINE 4LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
LIABILITY UNDER FIN 48 FOOTNOTESCHEDULE D, PAGE 3, PART XLLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2013 AND 2012.
REVENUE AMOUNTS INCLUDED IN FINANCIALS - OTHERSCHEDULE D, PAGE 4, PART XI, LINE 2DLLS CANADA REVENUE 13,446,524 ROUNDING -305
REVENUE AMOUNTS INCLUDED ON RETURN - OTHERSCHEDULE D, PAGE 4, PART XI, LINE 4BLSRP CONTRIBUTION 681,316
EXPENSE AMOUNTS INCLUDED IN FINANCIALS - OTHERSCHEDULE D, PAGE 4, PART XII, LINE 2DLLS CANADA EXPENSES 13,101,520 FOREIGN CURRENCY TRANSALATION ADJUSTMENT 83,698 ROUNDING 1,506
SUPPLEMENTAL FINANCIAL INFORMATIONSCHEDULE D, PAGE 4, PART XIIILLS MAINTAINS A SMALL PHOTOGRAPH COLLECTION FOR PUBLIC EXHIBITION WHICH HAS AN ESTIMATED VALUE OF BETWEEN 20,000 AND 50,000. AS THIS REPRESENTS A RELATIVELY SMALL PERCENTAGE OF LLS'S ASSETS, IT IS NOT SEPARATELY DISCLOSED IN THE FINANCIAL STATEMENTS OR FOOTNOTES.

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedtrueGrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (4 entries)

RegionRegionNumber Of OfficesNumberOfOfficesNumber Of EmployeesNumberOfEmployeesType Of Activities ConductedTypeOfActivitiesConductedSpecific Services ProvidedSpecificServicesProvidedTotal ExpendituresTotalExpenditures
EAST ASIA22RESEARCH FUNDINGRESEARCH GRANTS436347
EUROPE67RESEARCH FUNDINGRESEARCH GRANTS762288
NORTH AMERICA712RESEARCH FUNDINGRESEARCH GRANTS1563666
CENTRAL AMERICA & CARIBBEANINVESTMENTSINVESTMENTS
FieldValueIRS element (for citing)
Subtotal Number Of Offices15SubtotalNumberOfOffices
Subtotal Number Of Employees21SubtotalNumberOfEmployees
Total Number Of Offices15TotalNumberOfOffices
Total Number Of Employees21TotalNumberOfEmployees
Subtotal Amount Spent23700532SubtotalAmountSpent
Total Amount Spent23700532TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (44 entries)

RegionRegionPurpose Of GrantPurposeOfGrantAmount Of Cash GrantAmountOfCashGrantManner Of Cash DisbursementMannerOfCashDisbursementMethod Of ValuationMethodOfValuation
EAST ASIA & PACIFICRESEARCH GRANT50000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT100000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT190657CHECKACCRUAL
EAST ASIA & PACIFICTHERAPY ACCELERATION95690CHECKACCRUAL
EUROPERESEARCH GRANT110000CHECKACCRUAL
EUROPERESEARCH GRANT65000CHECKACCRUAL
EUROPERESEARCH GRANT50000CHECKACCRUAL
EUROPERESEARCH GRANT100000CHECKACCRUAL
EUROPETHERAPY ACCELERATION331503CHECKFMV
EUROPETHERAPY ACCELERATION82300CHECKFMV
EUROPETHERAPY ACCELERATION23485CHECKFMV
NORTH AMERICARESEARCH GRANT200000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT50000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT55000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT505594CHECKACCRUAL
NORTH AMERICARESEARCH GRANT100000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT55000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT241290CHECKACCRUAL
NORTH AMERICARESEARCH GRANT55000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT100000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT100000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT100000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT50000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT100000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT190657CHECKACCRUAL
EAST ASIA & PACIFICTHERAPY ACCELERATION95690CHECKACCRUAL
EUROPERESEARCH GRANT110000CHECKACCRUAL
EUROPERESEARCH GRANT65000CHECKACCRUAL
EUROPERESEARCH GRANT50000CHECKACCRUAL
EUROPERESEARCH GRANT100000CHECKACCRUAL
EUROPETHERAPY ACCELERATION331503CHECKFMV
EUROPETHERAPY ACCELERATION82300CHECKFMV
EUROPETHERAPY ACCELERATION23485CHECKFMV
NORTH AMERICARESEARCH GRANT200000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT50000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT55000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT505594CHECKACCRUAL
NORTH AMERICARESEARCH GRANT100000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT55000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT241290CHECKACCRUAL
NORTH AMERICARESEARCH GRANT55000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT100000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT100000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT100000CHECKACCRUAL
FieldValueIRS element (for citing)
Total Number Of Other Orgs16TotalNumberOfOtherOrgs
Transfer To Foreign CorptrueTransferToForeignCorp
Interest In Foreign TrustfalseInterestInForeignTrust
Own Foreign CorptrueOwnForeignCorp
Passive Foreign Invest CotruePassiveForeignInvestCo
Foreign PartnershipfalseForeignPartnership
Boycott CountriesfalseBoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV (2 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS OUTSIDE THE UNITED STATESSCHEDULE F, PAGE 1, PART I, LINE 2FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT.
ACTIVITIES PER REGIONSCHEDULE F, PAGE 1, PART I, LINE 3EAST ASIA 436,347 0 EUROPE 762,288 0 NORTH AMERICA 1,563,666 0 CENTRAL AMERICA & CARIBBEAN 0 20,938,231

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsXMailSolicitations
Email SolicitationsXEmailSolicitations
Phone SolicitationsXPhoneSolicitations
In Person SolicitationsXInPersonSolicitations
Solicitation Of Non Govt GrantsXSolicitationOfNonGovtGrants
Solicitation Of Govt GrantsXSolicitationOfGovtGrants
Special Fundraising EventsXSpecialFundraisingEvents
Agreement Ref FundraisingtrueAgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation (7 entries)

Address Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeActivityActivityFundraiser Control Of FundsFundraiserControlOfFundsAmount Retained By ContractorAmountRetainedByContractorNet To OrganizationNetToOrganization
MAIL AMERICA COMMUNICATIONS INC
174 ELKTON FARM ROADFORESTVA24551DIRECT MAIfalse4010903-4010903
INFOCISION
325 SPRINSIDE DRIVEAKRONOH44333TELEMARKETfalse1791410-1791410
PARADYZ MATERA
5 HANOVER SQUARE 6TH FLOORNEW YORKNY10004DIRECT MAIfalse1766306-1766306
DIRECT PRINT COMMUNICATIONS
201 EAST SANDPOINTE SUITE 400SANTA ANACA92707DIRECT MAIfalse1382841-1382841
THOMPSON HABIB & DENISON
80 HAYDEN AVENUE SUITE 300LEXINGTONMA02421DIRECT MAIfalse670953-670953
DONOR CARE CENTER INC
4345 STRAUSSSER ST NWNOTH CANTONOH44720TELEMARKETfalse400252-400252
BLACKBAUD
1800 DIAGONAL ROAD SUITE 400ALEXANDRIAVA22314DIRECT MAIfalse111823-111823
FieldValueIRS element (for citing)
Total Retained By Contractors10134488TotalRetainedByContractors
Total Net To Organization-10134488TotalNetToOrganization
All StatesAll StatesAllStates

Events Information EventsInformation

FieldValueIRS element (for citing)
Name Of Event1NIKE WOMEN HALFNameOfEvent1
Gross Receipts Event16347050GrossReceiptsEvent1
Charitable Contributions Event15108549CharitableContributionsEvent1
Gross Revenue Event11238501GrossRevenueEvent1
Other Direct Expenses Event11238501OtherDirectExpensesEvent1
Name Of Event2NIKE WOMENS MARNameOfEvent2
Gross Receipts Event29777032GrossReceiptsEvent2
Charitable Contributions Event26741163CharitableContributionsEvent2
Gross Revenue Event23035869GrossRevenueEvent2
Other Direct Expenses Event23035869OtherDirectExpensesEvent2
Total Number Of Other Events1050TotalNumberOfOtherEvents
Gross Receipts Other Events178435083GrossReceiptsOtherEvents
Charitable Contrib Other Events149412185CharitableContribOtherEvents
Gross Revenue Other Events29154898GrossRevenueOtherEvents
Other Direct Expenses Other Events29154898OtherDirectExpensesOtherEvents
Gross Receipts Total194559165GrossReceiptsTotal
Charitable Contributions Total161261897CharitableContributionsTotal
Gross Revenue Total Events33429268GrossRevenueTotalEvents
Other Direct Expenses Total Events33429268OtherDirectExpensesTotalEvents
Direct Expense Summary Events33429268DirectExpenseSummaryEvents

Gaming Information GamingInformation

FieldValueIRS element (for citing)
Volunteer Labor BingofalseVolunteerLaborBingo
Volunteer Labor Pull TabsfalseVolunteerLaborPullTabs
Gross Revenue Other Gaming778030GrossRevenueOtherGaming
Cash Prizes Other Gaming13067CashPrizesOtherGaming
Non Cash Prizes Other Gaming263649NonCashPrizesOtherGaming
Rent Facility Costs Other Gaming25239RentFacilityCostsOtherGaming
Other Direct Expenses Other Gaming19162OtherDirectExpensesOtherGaming
Volunteer Labor Other GamingtrueVolunteerLaborOtherGaming
Volunteer Labor Prcnt Other Gaming0.09000VolunteerLaborPrcntOtherGaming
Gross Revenue Total Gaming778030GrossRevenueTotalGaming
Cash Prizes Total Gaming13067CashPrizesTotalGaming
Non Cash Prizes Total Gaming263649NonCashPrizesTotalGaming
Rent Facility Costs Total Gaming25239RentFacilityCostsTotalGaming
Other Direct Expenses Total Gaming19162OtherDirectExpensesTotalGaming
Direct Expense Summary Gaming321117DirectExpenseSummaryGaming
Net Gaming Income Summary456913NetGamingIncomeSummary
FieldValueIRS element (for citing)
LicensedtrueLicensed
License Suspended EtcfalseLicenseSuspendedEtc
Gaming With NonmembersfalseGamingWithNonmembers
Member Of Other EntityfalseMemberOfOtherEntity
Percentage Of Gaming Own Facility0.01000PercentageOfGamingOwnFacility
Percentage Of Gaming Othr Facility0.99000PercentageOfGamingOthrFacility
Name Of Gaming Rec Keeper PersonROSEMARIE LOFFREDONameOfGamingRecKeeperPerson

Address Of Gaming Rec Keeper US AddressOfGamingRecKeeperUS

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1
CityWHITE PLAINSCity
StateNYState
ZIP Code10605ZIPCode
FieldValueIRS element (for citing)
Contract With3rd Party For Gam RevfalseContractWith3rdPartyForGamRev
Gaming Manager Name PersonSEE SCHEDULE G PART IVGamingManagerNamePerson
Charitable Distrib RequiredfalseCharitableDistribRequired

Form990 Schedule G Part IV Form990ScheduleGPartIV

FieldValueIRS element (for citing)
ExplanationSCHEDULE G PART I LINE 2B LLS USED INFOCISON MAIL AMERICA COMMUNICATIONS DONOR CARE CENTER INC AND THOMPSON HABIB DENISON FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS THESE PROGRAMS GENERATED GROSS RECEIPTS OF 21722519 DURING FISCAL YEAR 2013 LLS USED DIRECT PRINT COMMUNICATIONS PARADYZ MATERA AND BLACKBAUD FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING FISCAL YEAR 2013 SCHEDULE G PART III LINE 9STATES WITH GAMING OPERATIONS ARIZONA CALIFORNIA CONNECTICUT DISTRICT OF COLUMBIA IOWA KANSAS LOUISIANA MARYLAND MICHIGAN MINNESOTA MISSISSIPPI NEW YORK NORTH CAROLINAOHIO OREGONPENNSYLVANIA RHODE ISLAND TEXAS WISCONSIN SCHEDULE G PART III LINE 16 THE LEUKEMIA LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFFExplanation

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Records MaintainedtrueRecordsMaintained

Recipient Table RecipientTable (335 entries)

Address Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeEIN Of RecipientEINOfRecipientIRC SectionIRCSectionAmount Of Cash GrantAmountOfCashGrantMethod Of ValuationMethodOfValuationPurpose Of GrantPurposeOfGrant
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVEBRONXNY104611316242253200000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVEBRONXNY104611316242253110000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVEBRONXNY104611316242253200000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZAHOUSTONTX77030741613878355000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZAHOUSTONTX770027416138783200000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 DUARTE ROADDUARTECA910109534322103200000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 DUARTE ROADDUARTECA910109534322103200000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 DUARTE ROADDUARTECA910109534322103200000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 DUARTE ROADDUARTECA910109534322103200000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVEBOSTONMA021080421038813200000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVEBOSTONMA02108042103881365000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVEBOSTONMA021080421038813110000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
75 FRANCIS STBOSTONMA0211504231290931250000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
75 FRANCIS STBOSTONMA021150423129093110000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
75 FRANCIS STBOSTONMA021150423129093100000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
101 HUNTINGTON AVE SUITE 300BOSTONMA021150423129093110000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
101 HUNTINGTON AVE SUITE 300BOSTONMA02115042312909365000ACCRUALRESEARCH GRANT
CALIFORNIA INSTITUTE OF TECHNOLOGY
1200 EAST CA BLVDPASADENACA91125951643307355000ACCRUALRESEARCH GRANT
CASE WESTERN RESERVE UNIVERSITY - S
10900 EUCLID AVENUECLEVELANDOH441063410189923200000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL CORPORATION
300 LONGWOOD AVBOSTONMA02108042774441355000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL CORPORATION
300 LONGWOOD AVBOSTONMA02108042774441355000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL MEDICAL CENTER
3333 BURNET AVENUECINCINNATIOH452293108339363200000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL MEDICAL CENTER
3333 BURNET AVENUECINCINNATIOH452293108339363110000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL MEDICAL CENTER
3333 BURNET AVENUECINCINNATIOH452293108339363200000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL MEDICAL CENTER
3333 BURNET AVENUECINCINNATIOH452293108339363200000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL LOS ANGELES
4650 SUNSET BLVDLOS ANGELESCA900019516909773200000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL OF BOSTON
300 LONGWOOD AVENUEBOSTONMA021080427744413200000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL OF BOSTON
300 LONGWOOD AVENUEBOSTONMA021080427744413200000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL OF BOSTON
300 LONGWOOD AVENUEBOSTONMA021080427744413323707FMVTHERAPY ACCELERATION
CLEVELAND CLINIC FOUNDATION
9500 EUCLID AVENUECLEVELANDOH441953407145853270000FMVTHERAPY ACCELERATION
CLEVELAND CLINIC FOUNDATION
9500 EUCLID AVENUECLEVELANDOH441953407145533200000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY100011355980933200000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY100011355980933200000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY10001135598093355000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY10001135598093355000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY100011355980933110000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY10001135598093355000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY10001135598093355000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY100011355980933110000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY100011355980933200000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NYNY10001135598093355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403110000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA0210804226304031250000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403110000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403110000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403110000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403110000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040365000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040365000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
44 BINNEY STREETBOSTONMA021080422630403200000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
44 BINNEY STREETBOSTONMA02108042263040355000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
44 BINNEY STREETBOSTONMA021080422630403388850FMVTHERAPY ACCELERATION
DUKE UNIVERSITY MEDICAL CENTER
3813 BOX RESEARCH DRIVEDURHAMNC277105605321293492061ACCRUALRESEARCH GRANT
DUKE UNIVERSITY MEDICAL CENTER
324 BLACKWLL STREETDURHAMNC277105605321293110000ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
201 DOWMAN DRIVEATLANTAGA303225805662563110000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA981092371560713200000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA98109237156071355000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA98109237156071355000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA98109237156071365000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA981092371560713200000ACCRUALRESEARCH GRANT
GHSU RESEARCH INSTITUTE INC
1120 15TH STREETAUGUSTAGA309125814182023344189FMVTHERAPY ACCELERATION
HARVARD UNIVERSITY
MASSACHUSETTS HALLCAMBRIDGEMA02138530199180355000ACCRUALRESEARCH GRANT
HARVARD UNIVERSITY
MASSACHUSETTS HALLCAMBRIDGEMA02138530199180355000ACCRUALRESEARCH GRANT
HARVARD UNIVERSITY
MASSACHUSETTS HALLCAMBRIDGEMA02138530199180365000ACCRUALRESEARCH GRANT
INDIANOPOLIS UNIVERSITY
620 UNION DRIVE ROOM 518INDIANAPOLISIN462013560189403200000ACCRUALRESEARCH GRANT
INSTITUTE OF BIOSCIENCES & TECHNOLO
400 HARVEY MITCHELL PARKWAY SOUTHCOLLEGE STATIONTX77845330328688365000ACCRUALRESEARCH GRANT
IMMUNE DISEASE INSTITUTE (AKA) THE
3 BLACKFAN CIRBOSTONMA0211504215852031250000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
3400 NORTH CHARLES STREETBALTIMOREMD212015205951103500000FMVTHERAPY ACCELERATION
JOHNS HOPKINS UNIVERSITY SCHOOL OF
3400 NORTH CHARLES STREETBALTIMOREMD212015205951103400000FMVTHERAPY ACCELERATION
JOHNS HOPKINS UNIVERSITY SCHOOL OF
3400 NORTH CHARLES STREETBALTIMOREMD212015205951103110000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
3400 NORTH CHARLES STREETBALTIMOREMD21201520595110365000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
3400 NORTH CHARLES STREETBALTIMOREMD21201520595110365000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
3400 NORTH CHARLES STREETBALTIMOREMD212015205951103110000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
3400 NORTH CHARLES STREETBALTIMOREMD212015205951103200000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
3400 NORTH CHARLES STREETBALTIMOREMD212015205951103110000ACCRUALRESEARCH GRANT
KUMC RESEARCH INSTITUTUTE INC
3901 RAINBOW BOULEVARD MS 1039KANSAS CITYKS661604812024023300000FMVTHERAPY ACCELERATION
LA JOLLA INSTITUTE FOR ALLERGY AND
9420 ATHENA CIRCLELA JOLLACA920373303286883200000ACCRUALRESEARCH GRANT
LA JOLLA INSTITUTE FOR ALLERGY AND
9420 ATHENA CIRCLELA JOLLACA92037330328688365000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
50 STANIFORD STREETBOSTONMA02108041564655365000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
50 STANIFORD STREETBOSTONMA021080415646553110000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
50 STANIFORD STREETBOSTONMA02108041564655365000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
50 STANIFORD STREETBOSTONMA021080415646553110000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
50 STANIFORD STREETBOSTONMA021080415646553200000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
50 STANIFORD STREETBOSTONMA021080415646553200000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
50 STANIFORD STREETBOSTONMA0210804156465531250000ACCRUALRESEARCH GRANT
MAYO CLINIC AZ
13400 EAST SHEA BLVDSCOTTSDALEAZ852508608001503200000ACCRUALRESEARCH GRANT
MAYO CLINIC AZ
13400 EAST SHEA BLVDSCOTTSDALEAZ852508608001503200000ACCRUALRESEARCH GRANT
MAYO CLINIC AZ
13400 EAST SHEA BLVDSCOTTSDALEAZ852508608001503200000ACCRUALRESEARCH GRANT
MAYO CLINIC AZ
13400 EAST SHEA BLVDSCOTTSDALEAZ852508608001503200000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
200 FIRST STREET SWROCHESTERMN559054160117023110000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
200 FIRST STREET SWROCHESTERMN559054160117023200000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
200 FIRST STREET SWROCHESTERMN559054160117023110000ACCRUALRESEARCH GRANT
MD ANDERSON CANCER CENTER
1515 HOLCOMBE BLVDHOUSTONTX77030746001118355000ACCRUALRESEARCH GRANT
MEDICAL COLLEGE OF WI INC
8701 WATERTOWN PLANK RD PO BOX 2MILWAUKEEWI532263908062613110000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING
633 THIRD AVENUENEW YORKNY100179121542673114350FMVTHERAPY ACCELERATION
MOFFITT CANCER CENTER AND RESEARCH
12902 MAGNOLIA DRTAMPAFL33612592451713365000ACCRUALRESEARCH GRANT
MOUNT SINAI SCHOOL OF MEDICINE
1079 ONE GUSTAVE L LEVY PLACENYNY1002913617119731250000ACCRUALRESEARCH GRANT
MOUNT SINAI SCHOOL OF MEDICINE
1428 MADISON AVENUENYNY100291361711973200000ACCRUALRESEARCH GRANT
MOUNT SINAI SCHOOL OF MEDICINE
1428 MADISON AVENUENYNY100291361711973110000ACCRUALRESEARCH GRANT
NATIONAL INSTITUTES OF HEALTH NIH
6705 ROCKLEDGE DRBETHESDAMD20892520858115355000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVECHICAGOIL606013626561133200000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVECHICAGOIL606013626561133200000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVECHICAGOIL606013626561133200000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVECHICAGOIL6060136265611331250000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVECHICAGOIL60601362656113355000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVECHICAGOIL60601362656113365000ACCRUALRESEARCH GRANT
NY UNIVERSITY SCHOOL OF MEDICINE
545 FIRST AVENUE GBH SC1-55NYNY1000113617119731250000ACCRUALRESEARCH GRANT
NY UNIVERSITY SCHOOL OF MEDICINE
545 FIRST AVENUE GBH SC1-55NYNY10001136171197365000ACCRUALRESEARCH GRANT
NY UNIVERSITY SCHOOL OF MEDICINE
545 FIRST AVENUE GBH SC1-55NYNY100011361711973200000ACCRUALRESEARCH GRANT
NY UNIVERSITY SCHOOL OF MEDICINE
545 FIRST AVENUE GBH SC1-55NYNY100011361711973200000ACCRUALRESEARCH GRANT
NY UNIVERSITY SCHOOL OF MEDICINE
545 FIRST AVENUE GBH SC1-55NYNY10001136171197365000ACCRUALRESEARCH GRANT
NY UNIVERSITY SCHOOL OF MEDICINE
545 FIRST AVENUE GBH SC1-55NYNY100011361711973110000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
281 W LANE AVENUECOLUMBUSOH43210316401599365000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
281 W LANE AVENUECOLUMBUSOH43210316401599365000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
281 W LANE AVENUECOLUMBUSOH432103164015993200000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
281 W LANE AVENUECOLUMBUSOH432103164015993200000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
281 W LANE AVENUECOLUMBUSOH4321031640159931250000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROADPORTLANDOR97239237083114355000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROADPORTLANDOR9723923708311431250000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROADPORTLANDOR9723923708311432222000FMVTHERAPY ACCELERATION
PENNSYLVANIA STATE UNIVERSITY
123 S BURROWES STSTATE COLLEGEPA168012313526853200000ACCRUALRESEARCH GRANT
PRESIDENT & FELLOWS OF HARVARD COLL
6TH FLOOR HOLYOKE CENTER 1350 MA ACAMBRIDGEMA021380421035803200000ACCRUALRESEARCH GRANT
PRINCETON UNIVERSITY
200 ELM DRIVEPRINCETONNJ085442106345013335145ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MN - T
450 MCNAMARA ALUMNI CENTER 200 OAKMINNEAPOLISMN554014160075133200000ACCRUALRESEARCH GRANT
RHODE ISLAND HOSPITAL
593 EDDY STREET ALDRICH 3-317PROVIDENCERI02903263020947365000ACCRUALRESEARCH GRANT
ROBERT WOOD JOHNSON MEDICAL SCHOOL
335 GEORGE STREET LIBERTY PLAZA 4TNEW BRUNSWICKNJ089012217763063200000ACCRUALRESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUENYNY10065131624158355000ACCRUALRESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUENYNY10065131624158365000ACCRUALRESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUENYNY10065131624158355000ACCRUALRESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUENYNY10065131624158355000ACCRUALRESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUENYNY10065131624158355000ACCRUALRESEARCH GRANT
SAINT JUDE CHILDREN'S RESEARCH HOSP
262 DANNY THOMAS PLACEMEMPHISTN38105620646012365000ACCRUALRESEARCH GRANT
SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROADLA JOLLACA920373304359543110000ACCRUALRESEARCH GRANT
SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROADLA JOLLACA920373304359543110000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY10001912154267355000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY10001912154267355000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY100019121542673110000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY100019121542673200000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY100019121542673200000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY10001912154267365000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY10001912154267365000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY100019121542673200000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY10001912154267355000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY100019121542673110000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY10065912154267355000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY100659121542673110000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY100659121542673500000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY100659121542673110000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENYNY10065912154267355000ACCRUALRESEARCH GRANT
SAINT LOUIS UNIVERSITY
3700 WEST PINE MALLST LOUISMO631044306548723200000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
9500 GILMAN DRIVELA JOLLACA920372371211313110000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
9500 GILMAN DRIVELA JOLLACA920372371211313200000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
340 PANAMA STREETSTANFORDCA94305237121131355000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
340 PANAMA STREETSTANFORDCA943052371211313500000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
340 PANAMA STREETSTANFORDCA943052371211313200000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
340 PANAMA STREETSTANFORDCA943052371211313110000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
340 PANAMA STREETSTANFORDCA94305237121131355000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
340 PANAMA STREETSTANFORDCA943052371211313100000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY MEDICAL CENTER
301 RAVENSWOOD AVENUE MAIL CODE 55MENLO PARKCA94025237121131365000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY MEDICAL CENTER
301 RAVENSWOOD AVENUE MAIL CODE 55MENLO PARKCA94025237121131355000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY MEDICAL CENTER
301 RAVENSWOOD AVENUE MAIL CODE 55MENLO PARKCA94025237121131365000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY MEDICAL CENTER
301 RAVENSWOOD AVENUE MAIL CODE 55MENLO PARKCA94025237121131365000ACCRUALRESEARCH GRANT
STOWERS INSTITUTE FOR MEDICAL RESEA
1000 EAST 50TH STREETKANSAS CITYMO64110431684454355000ACCRUALRESEARCH GRANT
SUNY UPSTATE MEDICAL UNIVERSITY
750 EAST ADAMS STREETSYRACUSENY132101413683613200000ACCRUALRESEARCH GRANT
SUNY UPSTATE MEDICAL UNIVERSITY - S
750 E ADAMS STSYRACUSENY132101413683613110000ACCRUALRESEARCH GRANT
TEMPLE UNIVERSITY
3400N BOARD STREETPHILADELPHIAPA191402313659713200000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE UNIVER
809 S MARSHFIELD AVENUE M/C 551CHICAGOIL606073760005113110000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
3615 CIVIC CENTER BLVDPHILADELPHIAPA191042313521663110000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
3615 CIVIC CENTER BLVDPHILADELPHIAPA191042313521663110000ACCRUALRESEARCH GRANT
THE HOSPITAL FOR SPECIAL SURGERY
535 EAST 70TH STREETNYNY100211367147493200000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
320 WEST 10TH AVENUECOLUMBUSOH4321031640159931250000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
2150 SHATTUCK AVENUEBERKELEYCA94720946002123365000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
2150 SHATTUCK AVENUEBERKELEYCA94720946002123365000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
2150 SHATTUCK AVENUEBERKELEYCA94720946002123355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVENUE SUITE 102LOS ANGELESCA90095956006143365000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVENUE SUITE 102LOS ANGELESCA900959560061433110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVENUE SUITE 102LOS ANGELESCA90095956006143355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVENUE SUITE 102LOS ANGELESCA900959560061433200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVELA JOLLACA9209395287249431250000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVELA JOLLACA920939528724943110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVELA JOLLACA92093952872494355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVELA JOLLACA920939528724943110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVELA JOLLACA920939528724943110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
505 PARNASSUS AVENUE SUITE M1286 BSAN FRANCISCOCA94143946036493355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA94607946036493355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA94607946036493365000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA94607946036493365000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA94607946036493355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA94607946036493355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA94607946036493355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA946079460364933200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1111 FRANKLIN STOAKLANDCA94607946036493355000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093110000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI481093860063093200000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
515 E JEFFERSON STANN ARBORMI48109386006309350000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
1500 E MEDICAL CENTER DRIVEANN ARBORMI481093860063093974091FMVTHERAPY ACCELERATION
THE RESEARCH INSTITUTE OF FOX CHASE
333 COTTMAN AVENUEPHILADELPHIAPA191112320030723200000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREETPHILADELPHIAPA191042313526853200000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREETPHILADELPHIAPA1910423135268531250000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREETPHILADELPHIAPA191042313526853200000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREETPHILADELPHIAPA19104231352685365000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREETPHILADELPHIAPA19104231352685365000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
900 EAST 57TH STREETCHICAGOIL606013621771393100000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
6030 S ELLIS AVECHICAGOIL606013621771393200000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
6030 S ELLIS AVECHICAGOIL60601362177139355000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
6030 S ELLIS AVECHICAGOIL606013621771393200000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
6030 S ELLIS AVECHICAGOIL606013621771393200000ACCRUALRESEARCH GRANT
TRUSTEES OF DARTMOUTH COLLEGE
6010 PARKHURST HALL SUITE 204HANOVERNH037550202221113200000ACCRUALRESEARCH GRANT
UNIV OF TX HEALTH SCIENCE CENTER AT
7703 FLOYD CURL DRIVESAN ANTONIOTX782290422630403200000ACCRUALRESEARCH GRANT
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1720 2ND AVENUE SOUTHBIRMINGHAMAL352943860063093110000ACCRUALRESEARCH GRANT
UNIVERSITY OF ARKANSAS FOR MEDICAL
4301 W MARKHAM STLITTLE ROCKAR722057160462423200000ACCRUALRESEARCH GRANT
UNIVERSITY OF CA AT SAN FRANCISCO
3333 CA ST SUITE 315SAN FRANCISCOCA94143946036493355000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
500 PARNASSUS AVESAN FRANCISCOCA941439516909773110000ACCRUALRESEARCH GRANT
UNIVERSITY OF CINCINNATI
51 GOODMAN DRIVE UNIVERSITY HALL SCINCINNATIOH452010422630403110000ACCRUALRESEARCH GRANT
UNIVERSITY OF COLORADO
3415 COLORADO AVE UCB 596AURORACO80045846000555337500ACCRUALRESEARCH GRANT
UNIVERSITY OF COLORADO
1250 14TH STREETDENVERCO802918460005553225000FMVTHERAPY ACCELERATION
UNIVERSITY OF COLORADO AT BOULDER
3100 MARINE STREETBOULDERCO80303846000555355000ACCRUALRESEARCH GRANT
UNIVERSITY OF COLORADO DENVER ANSC
13001 E 17TH PLACEAURORACO800458760005253200000ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
113001 PO BOXGAINESVILLEFL326015960020523835253ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
GAINESVILLEGAINESVILLEFL326115960020523110000ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
GAINESVILLEGAINESVILLEFL326015960020523200000ACCRUALRESEARCH GRANT
UNIVERSITY OF MA MEDICAL SCHOOL
364 PLANTATION STREETWORCESTERMA01605043167352355000ACCRUALRESEARCH GRANT
UNIVERSITY OF MA MEDICAL SCHOOL
364 PLANTATION STREETWORCESTERMA016050431673523110000ACCRUALRESEARCH GRANT
UNIVERSITY OF MD BALTIMORE
220 ARCH STREET OFFICE LEVEL 2 ROBALTIMOREMD212015260020333200000ACCRUALRESEARCH GRANT
UNIVERSITY OF MD BALTIMORE
220 ARCH STREET OFFICE LEVEL 2 ROBALTIMOREMD212015260020333200000ACCRUALRESEARCH GRANT
UNIVERSITY OF MICHIGAN
1500 E MEDICAL CENTER DRIVEANN ARBORMI481093860063093200000ACCRUALRESEARCH GRANT
UNIVERSITY OF MICHIGAN
1500 E MEDICAL CENTER DRIVEANN ARBORMI481093860063093200000ACCRUALRESEARCH GRANT
UNIVERSITY OF MICHIGAN
1500 E MEDICAL CENTER DRIVEANN ARBORMI481093860063093110000ACCRUALRESEARCH GRANT
UNIVERSITY OF MICHIGAN
1600 HURON PARKWAY 2ND FLOORANN ARBORMI48109386006309334982FMVTHERAPY ACCELERATION
UNIVERSITY OF MN TWIN CITIES
321 CHURCH STREET SEMINNEAPOLISMN554017603008163110000ACCRUALRESEARCH GRANT
UNIVERSITY OF NEBRASKA MEDICAL CENT
985100 NEBRASKA MEDICAL CENTEROMAHANE681054700491233200000ACCRUALRESEARCH GRANT
UNIVERSITY OF NORTH CAROLINA AT CHA
450 WEST DRIVECHAPEL HILLNC27599566001393355000ACCRUALRESEARCH GRANT
UNIVERSITY OF PENNSYLVANIA
421 CURIE BOULEVARD BRBII/IIIRM 53PHILADELPHIAPA191042313526853200000ACCRUALRESEARCH GRANT
UNIVERSITY OF PENNSYLVANIA
3451 WALNUT STREETPHILADELPHIAPA19104231352685355000ACCRUALRESEARCH GRANT
UNIVERSITY OF ROCHESTER
601 ELMWOOD AVENUEROCHESTERNY146031604732093200000ACCRUALRESEARCH GRANT
UNIVERSITY OF ROCHESTER
601 ELMWOOD AVENUEROCHESTERNY146031604732093200000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307603008163110000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307603008163200000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307603008163110000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307603008163110000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307603008163110000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307603008163200000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307603008163500000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307603008163200000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
30 NORTH 1900E RM 1C26 SOMSALT LAKE CITYUT841128760005253200000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
30 NORTH 1900E RM 1C26 SOMSALT LAKE CITYUT84112876000525355000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
30 NORTH 1900E RM 1C26 SOMSALT LAKE CITYUT841128760005253200000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
30 NORTH 1900E RM 1C26 SOMSALT LAKE CITYUT841128760005253200000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
30 NORTH 1900E RM 1C26 SOMSALT LAKE CITYUT841128760005253200000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
30 NORTH 1900E RM 1C26 SOMSALT LAKE CITYUT841128760005253110000ACCRUALRESEARCH GRANT
UNIVERSITY OF WASHINGTON
1100 NE 45TH STREETSEATTLEWA981059160015373200000ACCRUALRESEARCH GRANT
UNIVERSITY OF WASHINGTON
1100 NE 45TH STREETSEATTLEWA98105916001537355000ACCRUALRESEARCH GRANT
UNIVERSITY OF WASHINGTON
1100 NE 45TH STREETSEATTLEWA981059160015373110000ACCRUALRESEARCH GRANT
UNIVERSITY OF WI-MADISON (BOARD OF
750 UNIVERSITY AVENUEMADISONWI537060422630403110000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVDDALLASTX753907603008163110000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVDDALLASTX753907603008163110000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVDDALLASTX753907603008163200000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVDDALLASTX75390760300816355000ACCRUALRESEARCH GRANT
VANDERBILT UNIVERSITY MEDICAL CENTE
3319 WEST END AVENUE SUITE 800NASHVILLETN372326204768223110000ACCRUALRESEARCH GRANT
VIRGINIA COMMONWEALTH UNIVERSITY
401 COLLEGE STREETRICHMONDVA232985460017583200000ACCRUALRESEARCH GRANT
WA UNIVERSITY OF SAINT LOUIS
660 SOUTH EUCLID AVENUEST LOUISMO631104306536113110000ACCRUALRESEARCH GRANT
WAKE FOREST UNIVERSITY
1834 WAKE FOREST ROADWINSTONSALEMNC271062238491993200000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY100011333766953200000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY10001133376695355000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY100011333766953200000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY100011333766953200000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY100011333766953200000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY100011333766953200000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY100011333766953200000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY100011333766953110000ACCRUALRESEARCH GRANT
WEILL MEDICAL COLLEGE OF CORNELL UN
575 LEXINGTON AVENUE 9TH FLOORNYNY10001133376695355000ACCRUALRESEARCH GRANT
WHITEHEAD INSTITUTE FOR BIOMEDICAL
9 CAMBRIDGE CENTERCAMBRIDGEMA021380610434123110000ACCRUALRESEARCH GRANT
WHITEHEAD INSTITUTE FOR BIOMEDICAL
9 CAMBRIDGE CENTERCAMBRIDGEMA02138061043412365000ACCRUALRESEARCH GRANT
WHITEHEAD INSTITUTE FOR BIOMEDICAL
9 CAMBRIDGE CENTERCAMBRIDGEMA02138061043412355000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
155 WHITNEY AVENUE PO BOX 208250NEW HAVENCT06510060646973355000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
155 WHITNEY AVENUE PO BOX 208250NEW HAVENCT06510060646973355000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
208250 PO BOXNEW HAVENCT065100606469733200000ACCRUALRESEARCH GRANT
ACETYLON PHARMACEUTICALS
70 FARGO STREETBOSTONMA02210263506788740000FMVTHERAPY ACCELERATION
BECKLOFF ASSOCIATES INC
3203 SOLUTIONS CENTERCHICAGOIL6067748084222325000FMVTHERAPY ACCELERATION
BIOSYNTHESIS INC
612 EAST MAIN STREETLEWISVILLETX7506775229719124400FMVTHERAPY ACCELERATION
CELATOR PHARMACEUTICALS
303B COLLEGE ROAD EASTPRINCETONNJ08540202680869740275FMVTHERAPY ACCELERATION
CONSTELLATION PHARMACEUTICALS
215 FIRST STREET SUITE 200CAMBRIDGEMA021422617417212000000FMVTHERAPY ACCELERATION
CURIS INC
4 MAGUIRE ROADLEXINGTONMA024210435051161650000FMVTHERAPY ACCELERATION
ONCONOVA THERAPEUTICS
375 PHEASANT RUNNEWTOWNPA18940223627252500000FMVTHERAPY ACCELERATION
INTEGRATED ANALYTICAL SOLUTION
1456 FOURTH STREET UNIT CBERKELEYCA9471020077669711025FMVTHERAPY ACCELERATION
MICROCONSTANTS INC
9050 CAMINO SANTA FESAN DIEGOCA9212133080950057895FMVTHERAPY ACCELERATION
NANOSYN
3100 CENTRAL EXPRESSWAYSANTA CLARACA95051860909295627175FMVTHERAPY ACCELERATION
PEPTISYNTHA INC
23424 NETWORK PLACECHICAGOIL6067376031529231772FMVTHERAPY ACCELERATION
SHAPE
55 CAMBRIDGE PARKWAYCAMBRIDGEMA02142263714475300000FMVTHERAPY ACCELERATION
SMITHERS PHARMA SERVICES
75711 PO BOXCLEVELANDOH4410120192211510500FMVTHERAPY ACCELERATION
VALOR BIOTHERAPEUTICS
15922 PO BOXCOLLEGE STATIONTX778414618837381300000FMVTHERAPY ACCELERATION
FieldValueIRS element (for citing)
Total Nbr Of501 C3 And Govt Grants321TotalNbrOf501C3AndGovtGrants
Total Nbr Of Other Organizations14TotalNbrOfOtherOrganizations

Form990 Schedule I Part III Form990ScheduleIPartIII (6 entries)

Type Of GrantTypeOfGrantNumber Of RecipientsNumberOfRecipientsAmount Of Cash GrantAmountOfCashGrant
PATIENT AID298942989442
COPAY ASSISTANCE CML705900000
COPAY ASSISTANCE CLL21063135550
COPAY ASSISTANCE LYMPHOMA823010984800
COPAY ASSISTANCE MDS14734320000
COPAY ASSISTANCE MYELOMA574523310000

Form990 Schedule I Part IV Form990ScheduleIPartIV

FieldValueIRS element (for citing)
IdentifierPROCEDURES FOR MONITORING THE USE OF GRANT FUNDS INSIDE THE UNITED STATESIdentifier
Return ReferenceSCHEDULE I, PAGE 1, PART I, LINE 2ReturnReference
ExplanationFIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT.Explanation

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeXCompensationCommittee
Independent ConsultantXIndependentConsultant
Form990 Of Other OrganizationsXForm990OfOtherOrganizations
Compensation SurveyXCompensationSurvey
Board Or Committee ApprovalXBoardOrCommitteeApproval
Severance PaymenttrueSeverancePayment
Supplemental Nonqual Retire PlanfalseSupplementalNonqualRetirePlan
Equity Based Comp ArrangementfalseEquityBasedCompArrangement
Comp Based On Revenue Of Filing OrgfalseCompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related OrgsfalseCompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing OrgfalseCompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate OrgsfalseCompBasedNetEarningsRelateOrgs
Any Non Fixed PaymentstrueAnyNonFixedPayments
Initial Contract ExceptionfalseInitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (8 entries)

TitleTitleBase Compensation Filing OrgBaseCompensationFilingOrgBonus Filing OrgBonusFilingOrgOther Compensation Filing OrgOtherCompensationFilingOrgDeferred Comp Filing OrgDeferredCompFilingOrgNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgTotal Compensation Filing OrgTotalCompensationFilingOrg
JOHN WALTER
PRESIDENT & CEO52000039000146223150023485628607
JAMES T NANGLE
SVP & CFO2165415508146792277223290282790
LOUIS DEGENNARO
CHIEF MISSION OFFICE33467029604177842500016269423327
RICHARD WINNEKER
SVP RESEARCH2540522241319777176081124314974
GEORGE OMIROS
CHIEF CAMPAIGN&FIELD2545278609164802500016135320751
KETING CHU
VP RES THERAPY227038615239829401813740290777
DAVID TIMKO
SVP VOLUNTEER ENGAGE235178176722408516106293041
NANCY KLEIN
CHIEF MKTG & REVENUE188136263405130139698474252

Form990 Schedule J Part III Form990ScheduleJPartIII (2 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
SEVERANCE, NONQUALIFIED, AND EQUITY-BASED PAYMENTSSCHEDULE J, PAGE 1, PART I, LINE 4NANCY KLEIN 254,754 0 0
NON-FIXED PAYMENTS PROVIDEDSCHEDULE J, PAGE 1, PART I, LINE 7BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF GROSS REVENUE EXCEEDING BUDGTED GROSS REVENUE, EMPLOYEE INDIVIDUAL PERFORMANCE AND OTHER METRICS. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B) (II).

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTraded

FieldValueIRS element (for citing)
Non Cash CheckboxXNonCashCheckbox
Number Of Contributions102NumberOfContributions
Noncash Contribs Rptd F9901094571NoncashContribsRptdF990
Method Of Determining RevenuesMARKET VALUEMethodOfDeterminingRevenues

Food Inventory FoodInventory

FieldValueIRS element (for citing)
Non Cash CheckboxXNonCashCheckbox
Number Of Contributions56NumberOfContributions

Other Non Cash Contributions Table OtherNonCashContributionsTable (3 entries)

Non Cash CheckboxNonCashCheckboxDescriptionDescriptionNumber Of ContributionsNumberOfContributions
XPRINTED ITEMS9
XFURNITURE&EQUIP2
XVARIOUS90
FieldValueIRS element (for citing)
Any Property That Must Be HeldfalseAnyPropertyThatMustBeHeld
Review Process Unusual NC GiftstrueReviewProcessUnusualNCGifts
Third Parties UsedfalseThirdPartiesUsed

Form990 Schedule M Part II Form990ScheduleMPartII (2 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
EXPLANATION FOR NOT REPORTING REVENUESCHEDULE M, PAGE 1, PART I, LINE 33LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.
SUPPLEMENTAL INFORMATIONSCHEDULE M, PAGE 2, PART IIPART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS.

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (17 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
FIRST ACCOMPLISHMENT DESCRIPTIONFORM 990, PAGE 2, PART III, LINE 4ACONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2013, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 72 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2013, FOR THE SECOND YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN THREE OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - THE MALIGNANT STEM CELL IN AML AND MDS - NON-CUTANEOUS T-CELL LEUKEMIAS AND LYMPHOMAS - HIGH RISK MYELOMA CASES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON AS POSSIBLE. THE PROGRAM INCLUDES: - THE ACADEMIC CONCIERGE DIVISION IDENTIFIES ESPECIALLY PROMISING LLS-FUNDED GRANT PROJECTS AND PROVIDES ADDITIONAL SUPPORT TO ADVANCE SELECTED PROJECTS TO THE PRODUCT STAGE. - THE BIOTECHNOLOGY ACCELERATOR DIVISION PARTNERS LLS WITH COMPANIES TO COMBINE SCIENTIFIC AND FINANCIAL RESOURCES AND ACCELERATE THE DEVELOPMENT OF POTENTIAL BLOOD CANCER THERAPIES THAT OTHERWISE MIGHT NOT BE PRIORITIZED BY THE COMPANY. - THE CLINICAL TRIALS DIVISION BRINGS CLINICAL TRIALS TO BLOOD CANCER PATIENTS IN THEIR COMMUNITIES, INCLUDING UNDER-REPRESENTED POPULATIONS, AND WITH THE ULTIMATE GOAL OF INCREASING PATIENT ENROLLMENT IN BLOOD CANCER TRIALS.
SECOND ACCOMPLISHMENT DESCRIPTIONFORM 990, PAGE 2, PART III, LINE 4BWEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH AND SPANISH. - 920,398 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2013 FINANCIAL ASSISTANCE IN 2013, A COMBINED 45,639,792 DOLLARS WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,989,442) AND CO-PAY ASSISTANCE PROGRAMS (42,650,350). PATIENT FINANCIAL AID PROGRAM FOR MORE THAN 46 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL AID PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL AID FUNDS ARE SUBJECT TO AVAILABILITY. - 29,894 PATIENTS RECEIVED FINANCIAL AID IN 2013 CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,259 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2013 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 34,809 PATIENT AND CAREGIVER PARTICIPANTS IN 2013 - 13,182 HEALTHCARE PROFESSIONAL PARTICIPANTS IN 2013 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 2,412 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 54 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2013. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 415 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 843 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 9,452 PARTICIPANTS IN FAMILY SUPPORT GROUPS IN 2013 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 6,322 FIRST CONNECTIONS IN 2013
THIRD ACCOMPLISHMENT DESCRIPTIONFORM 990, PAGE 2, PART III, LINE 4COUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 6 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 54,682 INQUIRIES IN 2013 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, PATIENT FINANCIAL AID, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL-TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2013, 14 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.
ALL OTHER ACCOMPLISHMENT DESCRIPTIONFORM 990, PAGE 2, PART III, LINE 4DD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.
FINANCIAL ACCOUNTS IN FOREIGN COUNTRIESFORM 990, PART V, LINE 4BCANADA
CLASSES OF MEMBERS OR STOCKHOLDERSFORM 990, PAGE 6, PART VI, LINE 6THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER.
ELECTION OF MEMBERS AND THEIR RIGHTSFORM 990, PAGE 6, PART VI, LINE 7ATHE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS.
DECISIONS SUBJECT TO APPROVAL OF MEMBERSFORM 990, PAGE 6, PART VI, LINE 7BSIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES.
ORGANIZATION'S PROCESS USED TO REVIEW FORM 990FORM 990, PAGE 6, PART VI, LINE 11BTHE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990 WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING BY POSTING THE FORM ON AN INTRANET WEBSITE.
ENFORCEMENT OF CONFLICTS POLICYFORM 990, PAGE 6, PART VI, LINE 12CALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE.
COMPENSATION PROCESS FOR TOP OFFICIALFORM 990, PAGE 6, PART VI, LINE 15ATHE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES.
COMPENSATION PROCESS FOR OFFICERSFORM 990, PAGE 6, PART VI, LINE 15BTHE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND COMPARED THIS TO THE OTHER OFFICER'S SALARY AND DETERMINED THAT IT WAS APPROPRIATE. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES.
STATES WHERE COPY OF RETURN IS FILEDFORM 990, PAGE 6, PART VI, LINE 17ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
GOVERNING DOCUMENTS DISCLOSURE EXPLANATIONFORM 990, PAGE 6, PART VI, LINE 19THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE, WHEN CHANGES ARE MADE, AS PART OF THE 990 AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.
GROUP RETURN METHODFORM 990, PAGE 7, PART VIIPARENT ORGANIZATION HAS FILED A CONSOLIDATED RETURN
RECONCILIATION OF CHANGES - OTHERFORM 990, PART XI, LINE 9LLS CANADA REVENUE 13,446,524 ROUNDING -305 LSRP CONTRIBUTION -681,316 LLS CANADA EXPENSES -13,101,520 FOREIGN CURRENCY TRANSALATION ADJUSTMENT -83,698 ROUNDING -1,506
OTHER CHANGES IN NET ASSETS EXPLANATIONFORM 990, PART XI, LINE 9CHANGE IN NET ASSETS LLS CANADA -345,004 LSRP CONNTRIBUTION 681,316 FINANCIAL STATEMENT ROUNDING 102

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII (3 entries)

Address Line1AddressForeign/AddressLine1CityAddressForeign/CityCountryAddressForeign/CountryPostal CodeAddressForeign/PostalCodePrimary ActivitiesPrimaryActivitiesLegal Domicile Foreign CountryLegalDomicileForeignCountryBusiness Name Line1DirectControllingEntityName/BusinessNameLine1Controlled OrgControlledOrgAddress Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeEINEINLegal Domicile StateLegalDomicileStateExempt Code SectionExemptCodeSectionPublic Charity StatusPublicCharityStatus
THE LLS OF CANADA
804 2 LANSING SQUARETORONTOCAM2J4P8PART VIICANAfalse
THE LLS RESEARCH PROGRAMS INC
PART VIILLS INCtrue1311 MAMARONECK AVENUEWHITE PLAINSNY10605133470494DE501C311B
THE LLS RESEARCH FOUNDATION
PART VIILLS INCtrue1311 MAMARONECK AVENUEWHITE PLAINSNY10605133709252DE501C311B
FieldValueIRS element (for citing)
Receipt Of Int Ann Rents RoyaltiesfalseReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other OrgfalseGiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other OrgtrueGiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other OrgtrueLoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other OrgfalseLoansOrGuaranteesFromOtherOrg
Dividends Related OrganizationfalseDividendsRelatedOrganization
Sale Of Assets To Other OrgfalseSaleOfAssetsToOtherOrg
Purchase Of Assets From Other OrgfalsePurchaseOfAssetsFromOtherOrg
Exchange Of AssetsfalseExchangeOfAssets
Rental Of Facilities To Other OrgsfalseRentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other OrgsfalseRentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other OrgsfalsePerformOfServicesForOtherOrgs
Perform Of Services By Other OrgsfalsePerformOfServicesByOtherOrgs
Sharing Of FacilitiestrueSharingOfFacilities
Sharing Of Paid EmployeestrueSharingOfPaidEmployees
Reimbursement Paid To Other OrgfalseReimbursementPaidToOtherOrg
Reimbursement Paid By Other OrgfalseReimbursementPaidByOtherOrg
Other Transfer To Other OrgfalseOtherTransferToOtherOrg
Other Transfer From Other OrgfalseOtherTransferFromOtherOrg

Transactions Related Orgs Table TransactionsRelatedOrgsTable (3 entries)

Transaction TypeTransactionTypeAmount InvolvedAmountInvolvedMethod Of Amt DeterminationMethodOfAmtDetermination
THE LEUKEMIA & LYMPHOMA SOCIETY
D146528COST
OF CANADA
THE LLS RESEARCH PROGRAMS INC
C681316COST

Form990 Schedule R Part VII Form990ScheduleRPartVII

FieldValueIRS element (for citing)
IdentifierGROUP EXEMPTION RELATIONSHIPSIdentifier
Return ReferenceSCHEDULE RReturnReference
ExplanationTHE LEUKEMIA LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA LYMPHOMA SOCIETY INC IN CANADA THE LEUKEMIA SOCIETY RESEARCH PROGRAMS INC AND THE LEUKEMIA RESEARCH FOUNDATION INC SUPPORT THE ACTIVITIES OF THE LEUKEMIA LYMPHOMA SOCIETY INCExplanation

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.